A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder (orvepitant MDD)

This study has been terminated.
(To allow assessment of isolated events of seizure during program)
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00880399
First received: April 9, 2009
Last updated: February 23, 2012
Last verified: March 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2010
  Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: February 23, 2012